Recent findings from a phase I study revealed that the sequential administration of nilotinib prior to doxorubicin treatment led to a reduction in ABCB1 activity in sarcoma patients, without a corresponding increase in cardiotoxicity. The gene discussed is ABCB1; the disease is sarcoma.